STAT6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL211691	0.50	8/20
Idarubicin (SCHEMBL4838)	0.98	5/20
Epirubicin (SCHEMBL94408)	0.92	5/20
Carubicin (SCHEMBL4201)	0.85	5/20
SCHEMBL94868	0.84	5/20
Zorubicin (SCHEMBL8231)	0.81	5/20
Zorubicin (SCHEMBL8232)	0.81	5/20
Idarubicin (SCHEMBL373859)	0.71	5/20
SCHEMBL19823	0.54	5/20
SCHEMBL343368	0.46	5/20
SCHEMBL57417	0.35	5/20
SCHEMBL57622	0.35	5/20
SCHEMBL88381	0.35	5/20
SCHEMBL58037	0.33	5/20
SCHEMBL58471	0.33	5/20
Epirubicin (SCHEMBL3165)	1.00	4/20
Doxorubicin (SCHEMBL3242)	1.00	4/20
Doxorubicin (SCHEMBL3243)	1.00	4/20
Idarubicin (SCHEMBL3750)	1.00	4/20
Epirubicin (SCHEMBL8582)	1.00	4/20

Clinical trials — most relevant to STAT6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial	PHASE2/PHASE3	UNKNOWN
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.	PHASE3	COMPLETED
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia	PHASE2	COMPLETED
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation	PHASE1/PHASE2	COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Ruxolitinib in Estrogen Receptor Positive Breast Cancer	PHASE2	COMPLETED
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients	PHASE1	RECRUITING
Itacitinib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma	EARLY_PHASE1	COMPLETED
STAT4 in Multiple Sclerosis by PCR and Flow Cytometry	nan	COMPLETED
Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients	nan	UNKNOWN
Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients	nan	COMPLETED
Immune Interactions in Severe Asthma	nan	COMPLETED
Cutaneous JAK in Vitiligo and Acne Vulgaris.	nan	UNKNOWN
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study	nan	WITHDRAWN
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts	nan	COMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C	nan	COMPLETED
Short-Term Application of Tocilizumab Following Myocardial Infarction	nan	COMPLETED
Androgenetic Alopecia and the JAK-STAT Pathway	nan	COMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma	nan	COMPLETED
Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases	nan	NOT_YET_RECRUITING
The Correlation Between Anemia of Chronic Diseases, Hepcidin and Vitamin D in IBD Patients	nan	UNKNOWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Effects of Probiotics on Peripheral Immunity in Parkinson's Disease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a STAT6 binder may also engage these)

Protein	Name	Similarity
P52633	—	0.996	P52633 →
P61635	—	0.979	P61635 →
Q7ZXK3	—	0.977	Q7ZXK3 →
P42227	—	0.975	P42227 →
Q9PVX8	—	0.975	Q9PVX8 →
P52631	—	0.973	P52631 →
Q3UR85	—	0.973	Q3UR85 →
P22682	—	0.972	P22682 →
Q98TY6	—	0.972	Q98TY6 →
P56477	—	0.971	P56477 →
CBL	E3 ubiquitin-protein ligase CBL	0.971	landscape →
Q6DV79	—	0.970	Q6DV79 →
Q80U62	—	0.970	Q80U62 →
A2SXS5	—	0.970	A2SXS5 →
STAT3	Signal transducer and activator of transcription 3	0.969	landscape →
Q8K4S7	—	0.968	Q8K4S7 →
P42225	—	0.968	P42225 →
Q9Y2G1	—	0.968	Q9Y2G1 →
Q19S50	—	0.968	Q19S50 →
Q92622	—	0.967	Q92622 →
O08773	—	0.967	O08773 →
Q9H3S7	—	0.967	Q9H3S7 →
Q13568	—	0.967	Q13568 →
NIBAN2	Protein Niban 2	0.967	landscape →
Q9NVU0	—	0.967	Q9NVU0 →
P12755	—	0.967	P12755 →
Q69Z89	—	0.967	Q69Z89 →
P97492	—	0.967	P97492 →
Q8C190	—	0.966	Q8C190 →
STAT1	Signal transducer and activator of transcription 1-alpha/beta	0.966	landscape →